787. Echinocandin Resistant Candida tropicalis Bloodstream Infections
Session: Poster Abstract Session: Treatment of Resistant Infections - Clinical Analyses
Thursday, October 5, 2017
Room: Poster Hall CD
Background:

The aim of this study is to describe the clinical manifestations, molecular mechanisms, and treatment outcomes of patients with echinocandin-resistant Candida tropicalis (C. tropicalis) bloodstream infections (BSI).

Methods:

A PubMed search was conducted using the search terms related to C. tropicalis BSI and echinocandin resistance. Two previously unreported cases from our institution diagnosed with C. tropicalisBSI that developed resistance to echinocandins were also included. Demographics, comorbidities, treatment, clinical outcomes, and molecular mechanisms were analyzed.

Results:

Seven patients with echinocandin-resistant C. tropicalis BSI were identified, including 5 previously reported cases and two from our institution. Median age was 58.7 ± 20.4 years; 3 (43%) patients were males. Three (43%) had acute myelogenous leukemia, 3 (43%) had acute lymphoblastic leukemia, and 1 (14%) had urothelial cancer. All patients were immunocompromised having received chemotherapy in the last six months and 3 (43%) were hematopoietic stem cell transplant recipients. Five (71%) had breakthrough of echinocandin resistance while receiving an echinocandin; one (14%) received caspofungin in the past 3 months and only one (14%) had no reported echinocandin exposure in the past 3 months.

DNA sequencing of the FKS1 gene for mutations known to confer echinocandin resistance was performed in 4 cases, including our two index cases. Homozygous T-to-C mutations in two alleles of FKS1gene was detected in 2 cases, and a heterozygous mutation was detected in the other 2 cases, which resulted in a deduced serine-to-proline amino acid change at position 654 (S654P).

Six patients (86%) survived after being treated with an antifungal agent other than an echinocandin. Treatment was changed to liposomal amphotericin B in two cases, and one each to voriconazole, fluconazole, voriconazole plus liposomal amphotericin B, and caspofungin plus voriconazole. The one patient who died received intravenous voriconazole.

Conclusion:

Echinocandin resistance emerged in neutropenic patients with C. tropicalis fungemia through a characteristic mutational hot-spot amino acid change in the target FKS1 gene. Although alternative antifungal agents may be successfully used as salvage therapy, the outcome may still be fatal.

Maroun Sfeir, MD, MPH1,2, Cristina Jiménez-Ortigosa, PhD3, Audrey Schuetz, MD4, Stephen Jenkins, PhD5, Sian Jones, MD6, Rosemary Soave, MD, FIDSA7, Koen Van Besien, MD, PhD7, Michael Satlin, MD8, Catherine Small, MD9, David Perlin, PhD10 and Thomas Walsh, MD, FIDSA11, (1)Medicine/ Division of Infectious Disease, New York-Presbyterian Hospital/ Weill Cornell Medicine, New York, NY, (2)Healthcare Policy & Research, Weill Cornell Medicine, New York, NY, (3)Public Health Research Institute, Rutgers Biomedical and Health Sciences, Newark, NJ, (4)Division of Clinical Microbiology, Mayo Clinic, Rochester, MN, (5)New York-Presbyterian Weill Cornell Medical Center, New York, NY, (6)Division of Infectious Diseases, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, (7)NewYork-Presbyterian Hospital / Weill Cornell Medical Center, New York, NY, (8)New York-Presbyterian, New York, NY, (9)Internal Medicine/Infectious Diseases, Weill Cornell Medical College, New York, NY, (10)PHRI-University of Medicine and Dentistry of New Jersey, Newark, NJ, (11)Transplantation-Oncology, Weill Cornell Medical College of Cornell University, New York City, NY

Disclosures:

M. Sfeir, None

C. Jiménez-Ortigosa, None

A. Schuetz, None

S. Jenkins, None

S. Jones, None

R. Soave, None

K. Van Besien, None

M. Satlin, None

C. Small, None

D. Perlin, Pfizer: Research support, honoraria and/or consulting fees and/or has served on advisory board , Research support, honoraria and/or consulting fees and/or has served on advisory board
Astrellas: Research support, honoraria and/or consulting fees and/or has served on advisory board , Research support, honoraria and/or consulting fees and/or has served on advisory board
Merck: Research support, honoraria and/or consulting fees and/or has served on advisory board , Research support, honoraria and/or consulting fees and/or has served on advisory board
Cidara: Research support, honoraria and/or consulting fees and/or has served on advisory board , Research support, honoraria and/or consulting fees and/or has served on advisory board
Synexis: Research support, honoraria and/or consulting fees and/or has served on advisory board , Research support, honoraria and/or consulting fees and/or has served on advisory board
F2G: Research support, honoraria and/or consulting fees and/or has served on advisory board , Research support, honoraria and/or consulting fees and/or has served on advisory board
Myconostica: Research support, honoraria and/or consulting fees and/or has served on advisory board , Research support, honoraria and/or consulting fees and/or has served on advisory board
Amplyx: Research support, honoraria and/or consulting fees and/or has served on advisory board , Research support, honoraria and/or consulting fees and/or has served on advisory board
Matinas: Research support, honoraria and/or consulting fees and/or has served on advisory board , Research support, honoraria and/or consulting fees and/or has served on advisory board
GAFFI: Scientific Advisor , Advisor
Bill and Melinda Gates Foundation: Scientific Advisor , Advisor

T. Walsh, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.